Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN38,9139,113,31
Msft1,01
Nokia2,78152,8005-18,63
IBM2,12
Daimler AG44,12544,15-0,05
PFE-0,48
30.10.2020 0:31:01
Indexy online
AD Index online
select
AD Index online
 

  • 29.10.2020 21:30:00
ANI Pharmaceuticals (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
26,32 -3,66 -1,00 61 592
After-hours29.10.2020 22:20:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
26,32 - - -3,66 -1,00
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 30.10.2020
Popis společnosti
Obecné informace
Název společnostiANI Pharmaceuticals Inc
TickerANIP
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares Class C
RICANIP.O
ISIN-
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 338
Akcie v oběhu k 31.07.2020 12 315 057
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice210 W Main St
MěstoBAUDETTE
PSČ56623-2467
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 186 343 500
Fax12186343540

Business Summary: ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Financial Summary: BRIEF: For the six months ended 30 June 2020, ANI Pharmaceuticals Inc revenues decreased 8% to $98.2M. Net loss applicable to common stockholders totaled $19.3M vs. income of $6.9M. Revenues reflect United States segment decrease of 8% to $94.5M, Canada segment decrease of 11% to $3.7M. Net loss reflects Stock-based Compensation in SGA increase of 99% to $7.7M (expense), Selling, General and administrative increase of 15% to $27.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Owners and Lessors of Other Non-Financial Assets
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICPatent Owners And Lessors



  • Poslední aktualizace: 30.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardPatrick Walsh5908.09.202011.05.2020
President, Chief Executive Officer, DirectorNikhil Lalwani4308.09.202008.09.2020
Corporate Secretary, Vice President, Finance and Chief Financial OfficerStephen Carey5006.05.201606.05.2016
Senior Vice President - New Business Development and Specialty SalesRobert Schrepfer4812.08.2013
Senior Vice President - Operations and Product DevelopmentJames Marken5719.06.2013